Related Tags >> Clinical Trial Results Phase II Bavituximab breast cancer

Peregrine News

Most Popular Peregrine Story

Peregrine posts promising data on Phase II lung cancer trial

October 5, 2009 — 10:28am ET | By John Carroll

Shares of Peregrine Pharmaceuticals (PPHM) shot up 14 percent after the biotech reported that its monoclonal antibody bavituximab in combination with chemo significantly improved the Read more...

Peregrine Press Releases

Peregrine Pharmaceuticals (PPHM) Presents Promising Phase II Survival Data in Recurrent GBM With Single Treatment of Cotara
Peregrine Reports Promising Interim Survival Data From Phase II Cotara(R) Brain Cancer Study
Peregrine Pharmaceuticals Reports Positive Results From Phase II Bavituximab Lung Cancer Trial
Peregrine Pharmaceuticals Adds Noted Oncologist Dr. Bruce Chabner as Clinical Advisor
Peregrine Pharmaceuticals, Inc.'s Bavituximab Achieves Primary Endpoint in First Stage of Phase II Breast Cancer Study

Latest Headlines

Peregrine shares spike on Ph2 cancer data
August 24, 2011
Peregrine shares spike on positive PhII brain cancer data
October 18, 2010
Peregrine posts promising data on Phase II lung cancer trial
October 5, 2009
Peregrine shares jump after drug demos brain cancer efficacy
September 2, 2009
Peregrine touts data for breast cancer
February 11, 2009

Paid Research Reports

More Research Reports >>